GEN Exclusives

More »

GEN News Highlights

Back to Item »

Daiichi Sankyo Licenses Phase I-Ready Cancer Drug Developed Through ArQule Partnership

ARQ 092 is first AKT inhibitor to emerge from collaboration that includes Phase III-stage tivantinib.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?